Merck & Co. (MRK) announced Friday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of ELONVA, as a treatment in controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program.
Merck & Co. climbed during the first half hour of trade Friday and rose further around mid-afternoon. The stock finished up by 1.13 at $36.46. Merck has been gaining ground for the last 2 1/2 weeks and closed at its fifth consecutive new high for the year.
For comments and feedback: editorial@rttnews.com